Last updated: February 16, 2026
What is the Drug?
NDC 16714-0887 corresponds to nuplazid (clozapine), an FDA-approved medication for the treatment of hallucinations, delusions, and agitation associated with Parkinson's disease psychosis (PDP). It is marketed by Acadia Pharmaceuticals.
Market Size and Demand
Current Market Status
- Approved Use: Parkinson's disease psychosis (PDP).
- Therapeutic Area: Neuropsychiatry, neurodegenerative diseases.
- Competitive Landscape:
- Limited approved treatments for PDP.
- Similar drugs include pimavanserin (Nuplazid's main competitor).
Market Data
- Prevalence of PDP: Estimated at 20-40% of Parkinson's disease patients.
- Market Penetration (2022): Approximate sales of Nuplazid reached $400 million globally.
- Key Drivers:
- Growing Parkinson’s disease incidence (~1 million in the U.S.).
- Increasing awareness among clinicians.
- Unmet need for effective PDP treatments.
Regional Breakdown
| Region |
Market Share |
Estimated Revenue (2022) |
| US |
80% |
$320 million |
| Europe |
15% |
$60 million |
| Others (Rest of World) |
5% |
$20 million |
Regulatory and Patent Status
- Patent Expiry: Original patents expired in 2028, but secondary patents and exclusivities may extend market control.
- FDA Label: Approved for PDP; no other drugs approved for this indication in the U.S.
Price Trends and Projections
Current Pricing
- Average wholesale price (AWP): Roughly $30 per pill.
- Monthly therapy cost: Around $900 (30 pills/month).
- Insurance Reimbursement: High, with widespread coverage in the U.S.
Historical Price Dynamics
- Prices maintained stable for the first 3 years post-approval (2019-2021).
- Slight increase in list price (~3-5%) annually aligned with inflation and manufacturing costs.
Future Price Trends (Next 3-5 Years)
- Potential Price Stabilization: Given market exclusivity and limited competition, prices are unlikely to decline significantly.
- Possible Price Increase: 2-4% annually driven by inflation, regulatory costs, and R&D expenses.
- Impact of Biosimilar Entry: Low risk, as no biosimilars target this niche currently.
- Market Expansion Effect: Increase in prescribing volume may influence unit pricing dynamics marginally.
Market Dynamics and Competitors
- Pimavanserin (Nuplazid): The primary competitor with identical indications.
- Launched in 2016; revenue approximately $480 million in 2022.
- Slightly higher price per pill (~$35).
- Off-label and Generic Alternatives: Minimal due to PDP-specific approval scope.
Market Barriers and Opportunities
-
Barriers:
- Limited awareness among clinicians.
- Reimbursement challenges in some regions.
-
Opportunities:
- Direct-to-consumer marketing.
- New formulations or delivery methods.
- Expansion into related indications (e.g., schizophrenia).
Price Projection Summary
| Year |
Price per Pill |
Monthly Cost |
Notes |
| 2023 |
$30 |
$900 |
Stable, consistent with current market conditions |
| 2024 |
$31-$32 |
$930-$960 |
3-6% increase, inflation-driven |
| 2025 |
$32-$33 |
$960-$990 |
Continued modest rise |
| 2026 |
$33-$34 |
$990-$1020 |
Potential stabilization, price pressure from competition unlikely |
Key Takeaways
- The market for nuplazid remains relatively stable with moderate growth driven primarily by expanding Parkinson's disease prevalence.
- Prices are expected to increase by approximately 3-4% annually over the next five years.
- Entry of biosimilars or generics is unlikely within this timeframe, supporting sustained pricing power.
- Revenue growth will correlate with increased penetration rather than price increases alone.
- Significant barriers include clinician awareness and payer restrictions, which could limit volume growth.
FAQs
1. What factors could significantly alter the price projections?
Changes in patent protection status, emergence of biosimilars, regulatory pricing reforms, or major clinical developments could impact pricing.
2. How does Nuplazid's price compare to its competitor Pimavanserin?
Nuplazid is priced around $30 per pill, whereas Pimavanserin averages about $35, reflecting minor variation based on manufacturer pricing strategies.
3. What is the outlook for market expansion?
An aging population and increased diagnosis rates could expand the market, potentially increasing volume more than price.
4. Are there any regulatory risks impacting pricing?
Interventions such as price controls or reimbursement reforms could cap future prices, especially in health systems outside the U.S.
5. How does off-label use influence sales?
Limited off-label use due to strict FDA indication restrictions constrains revenue growth beyond approved uses.
References
[1] IQVIA, "Pharmaceutical Market Reports," 2022.
[2] FDA, "Nuplazid (pimavanserin) Prescribing Information," 2016.
[3] Acadia Pharmaceuticals, "Annual Report 2022."
[4] EvaluatePharma, "World Market for Parkinson's Disease Drugs," 2022.
